Gupta Aditya K, Paquet Maryse
J Cutan Med Surg. 2014 May-Jun;18(3):151-5. doi: 10.2310/7750.2013.13095.
Topical therapies for onychomycosis are associated with less adverse events than systemic therapies, but poor nail penetration limits their efficacy. Consequently, an efinaconazole 10% nail solution was developed.
To review the evidence supporting the usefulness of efinaconazole monotherapy in onychomycosis management.
PubMed and clinicaltrials.gov databases and abstracts from the 2013 annual meeting of the American Academy of Dermatology were searched in April 2013 using the terms "efinaconazole," "IDP-108," and "KP-103."
In vitro, efinaconazole possesses a broad antifungal activity similar or superior to that of other antifungals. Its low affinity for keratin results in good nail penetration. Efinaconazole 10% nail solution administered daily for 36 or 48 weeks to treat mild to moderate toenail onychomycosis caused by dermatophytes results in complete and mycologic cure rates of 15 to 25% and 53 to 87%, respectively. No serious skin reaction is associated with its use.
Efinaconazole 10% nail solution is a promising new treatment for onychomycosis.
甲癣的局部治疗与全身治疗相比，不良事件较少，但指甲穿透力差限制了其疗效。因此，开发了10%的艾氟康唑甲溶液。
综述支持艾氟康唑单药治疗甲癣有效性的证据。
2013年4月，使用“艾氟康唑”“IDP - 108”和“KP - 103”等检索词，检索了PubMed、clinicaltrials.gov数据库以及美国皮肤病学会2013年年会的摘要。
在体外，艾氟康唑具有广泛的抗真菌活性，与其他抗真菌药物相似或更优。其对角蛋白的低亲和力导致良好的指甲穿透力。每日使用10%的艾氟康唑甲溶液治疗由皮肤癣菌引起的轻至中度趾甲甲癣36周或48周，完全治愈率和真菌学治愈率分别为15%至25%和53%至87%。使用该药物未出现严重皮肤反应。
10%的艾氟康唑甲溶液是一种有前景的甲癣新治疗方法。
